Covax Pharmaceutical: Net profit is expected to increase by 394.17% year-on-year in 2025, planning to distribute a dividend of 2.5 yuan per share.

On April 21st, Kexing Pharmaceuticals disclosed its annual report, achieving operating income of 1.534 billion yuan in 2025, a year-on-year increase of 9.03%; net profit attributable to the parent company was 156 million yuan, a year-on-year increase of 394.17%; basic earnings per share were 0.79 yuan. The company plans to distribute a cash dividend of 2.5 yuan for every 10 shares. During the reporting period, the company actively explored overseas markets, achieving strong growth in overseas income, driving continuous growth in operating income and a significant increase in profitability.